Semaglutide in HFpEF: German cost analysis

A new pharmacoeconomic analysis finds that semaglutide is cost-effective for treating heart failure with preserved ejection fraction (HFpEF) in patients with obesity within the German statutory health insurance system, but the budget impact could run into the hundreds of millions of euros^[1]. Published in PharmacoEconomics on 2 June 2026, the study by Estler and colleagues models five-year and one-year cost outcomes based on data from the STEP-HFpEF randomised trial^[2].

The numbers: cost per QALY at five years

The researchers built a cohort state-transition model comparing semaglutide against placebo from the perspective of German statutory health insurance (gesetzliche Krankenversicherung, or GKV). Over five years, total per-patient costs were 17,690 EUR in the semaglutide arm versus 12,749 EUR in the placebo arm. Patients on semaglutide gained 3.371 quality-adjusted life years (QALYs), compared with 3.208 on placebo. That produces an incremental cost-effectiveness ratio (ICER) of 30,443 EUR per QALY gained^[1].

The incremental net monetary benefit was positive, and in probabilistic sensitivity analysis, the probability of semaglutide being cost-effective reached 0.911 at a willingness-to-pay threshold of 100,000 EUR per QALY^[1]. In plain terms: across a wide range of plausible input assumptions, the model found semaglutide more likely than not to deliver health gains that justify its cost over five years.

The one-year picture is less favourable

At a shorter one-year time horizon, the ICER rose to 82,237 EUR per QALY^[1]. The difference matters because Germany does not enforce a single formal cost-effectiveness threshold the way NICE does in the UK. Instead, the Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in Health Care (IQWiG) assess added benefit on a case-by-case basis, and pricing negotiations between manufacturers and statutory insurers follow. In that context, the one-year ICER signals that semaglutide's value proposition in HFpEF depends on sustained use over multiple years, not short courses.

Budget impact: 168 million to 864 million EUR

The study also ran a budget-impact analysis across several uptake scenarios. Depending on how many eligible patients start treatment and how long they remain on it, the annual budget impact to German statutory health insurance ranges from roughly 168 million EUR to 864 million EUR^[1]. That range reflects genuine uncertainty: the eligible population (adults with HFpEF and obesity) is large, but real-world uptake is hard to predict when the indication sits outside semaglutide's current core marketing as a weight-management and diabetes drug.

What this does not tell us

The model is based on the STEP-HFpEF trial, which tested semaglutide 2.4 mg weekly in patients with HFpEF and a BMI of 30 or above^[2]. That trial measured symptoms, physical function, and weight loss over 52 weeks. It did not measure hard cardiovascular endpoints like hospitalisation for heart failure or death. Cost-effectiveness projections over five years therefore rely on modelling assumptions about how symptom improvements translate into long-term outcomes and costs. The authors acknowledge this limitation explicitly.

The analysis also does not address whether German regulators will approve semaglutide specifically for HFpEF. As of June 2026, Wegovy is authorised in the EU for chronic weight management, and Ozempic for type-2 diabetes^[3], but neither label covers heart failure as a standalone indication. Any real-world budget impact depends on a label expansion or off-label prescribing patterns that the study does not model.

There is also a practical question the study leaves open: who pays during the gap between clinical evidence and formal reimbursement? In Germany, the AMNOG process (the law governing drug-pricing negotiations between manufacturers and statutory insurers) requires a G-BA benefit assessment before a negotiated price takes effect. Until semaglutide receives a positive benefit assessment for HFpEF specifically, reimbursement through the GKV is not guaranteed, and prescribing would depend on individual insurer willingness to cover off-label use.

Where this fits

This is the first published cost-effectiveness analysis of semaglutide for HFpEF in a European healthcare system. It adds an economic dimension to the clinical evidence from STEP-HFpEF and positions the drug's value argument ahead of any regulatory or reimbursement decision in Germany. For readers following semaglutide's expanding evidence base, this study illustrates how the conversation is shifting from "does it work?" to "can systems afford it?"

Semaglutide is a prescription-only GLP-1 receptor agonist across the EU, UK and US. See our semaglutide overview for the full clinical profile, and the Germany regulation page for country-specific prescribing and reimbursement context.